The global enteral feeding market is projected to grow at a significant CAGR during the forecast period. Numerous players are operating in the global enteral feeding industry providing dietary supplements and devices for enteral feeding. The players operating in the market are adopting various growth strategies and contributing to the growth of the market. Product launches & developments, partnerships, agreements, and acquisitions are among some of the strategies adopted by the players to sustain in a competitive market. With these activities, the players aim to expand their share in the enteral feeding landscape and hence expand the global enteral feeding size.
Browse the full report description of "Global Enteral Feeding Market Size, Share & Trends Analysis Report by Product (Formulas and Devices), By Age Group (Pediatric and Adults), By Application (Oncology, Diabetes, Gastroenterology, Neurological Disorders, and Others), By End-User (Hospitals and Home Care) Forecast, 2019-2025" at https://www.omrglobal.com/industry-reports/enteral-feeding-market
Players such as Abbott Laboratories Inc., B. Braun Melsungen AG, Becton, Dickinson, and Co., Boston Scientific Corp., C. R. Bard Inc., Mead Johnson & Co. LLC, Medtronic Plc, Moog, Inc., Nestlé S.A., and Vygon SA are significantly contributing to the market growth.
In December 2018, Nestlé Health Science started its new Nestlé Product Technology Center in New Jersey to establish a global R&D hub for improving the company’s product portfolio in the nutrition division. The company opened the novel center with an investment of $70 million.
In October 2018, Danone Nutricia Research of Group Danone launched novel packaging for its OpTri bottle, sip feed product. It amalgamated the design of both bottle and pouch for enhancing patient usability and safety and to eliminate medical waste.
In August 2018, Alcresta Therapeutics, Inc. showcased the results from the clinical trial on RELiZORB cartridge. The short-term result in the age group of 5 to 34 years with Cystic Fibrosis (CF) associated with Exocrine Pancreatic Insufficiency (EPI), exhibited that the plasma concentration of EPA and DHA increased by 2.8 folds with RELiZORB. Whereas, the long-term result in patients with CF, depicted the upsurge in red blood cells of DHA and EPA, for pediatric and adult patients with cystic fibrosis to hydrolyze fats in enteral formulas.
In December 2017, C. R. Bard Inc. was acquired by Becton, Dickinson, and Co. for infection prevention and medication management sectorsand to extend its product offerings in the medical devices sector.
In January2017, Nestle Health Science, under its product line for both adult and children population, introduced three novel sip feed products. It includes a variety of ingredients such as proteins, vitamins, real food, and minerals among other ingredients.
Such activities performed by the market players enable them to gain maximum share in the market and sustain in the competitive environment and hence contribute to the growth of the global enteral feeding market.
Global Enteral Feeding Market – Segmentation
By Product
o Standard Formulas
o Disease-Specific Formulas
o Enteral Feeding Pumps
o Enteral Feeding Tubes
o Others
By Age Group
By Application
By End-User
Global Enteral Feeding Market – Segmentation by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/enteral-feeding-market